| P50 | author | Hans-Christoph Diener | Q25935337 |
| P2093 | author name string | Ralph Weber | |
| P2860 | cites work | Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients | Q24555072 |
| | Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke | Q24646522 |
| | Pathobiology of ischaemic stroke: an integrated view | Q28141682 |
| | Cerebral microbleeds as a risk factor for subsequent intracerebral hemorrhages among patients with acute ischemic stroke | Q28165225 |
| | Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial | Q28174292 |
| | S18886, a selective TP receptor antagonist, inhibits development of atherosclerosis in rabbits | Q28177053 |
| | Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events | Q28192726 |
| | Aspirin resistance | Q28195157 |
| | Improved endothelial function by the thromboxane A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin | Q28195607 |
| | Adherence to secondary stroke prevention strategies--results from the German Stroke Data Bank | Q28195639 |
| | Lack of reproducibility of assessment of aspirin responsiveness by optical aggregometry and two platelet function tests | Q45875469 |
| | Aspirin noncompliance is the major cause of "aspirin resistance" in patients undergoing coronary stenting | Q46045981 |
| | Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients | Q46047927 |
| | Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study | Q46088369 |
| | Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance". | Q46114498 |
| | Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk | Q46329223 |
| | Prasugrel in the poststroke cohort of the TRITON Trial: the clear and present danger | Q46544812 |
| | Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study | Q46611942 |
| | Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A randomized, double-blind, aspirin-controlled trial | Q46664642 |
| | Inhibition of 5-hydroxytryptamine receptor prevents occlusive thrombus formation on neointima of the rabbit femoral artery | Q46892256 |
| | Prasugrel versus clopidogrel in patients with acute coronary syndromes | Q46915044 |
| | Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. | Q48785632 |
| | Vascular endothelium and the blood-brain barrier | Q48925865 |
| | Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. | Q50357085 |
| | Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: Design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)- | Q57313076 |
| | Guidelines for Management of Ischaemic Stroke and Transient Ischaemic Attack 2008 | Q57812917 |
| | The central role of the P2T receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity | Q61669028 |
| | Atherothrombosis--wave goodbye to combined anticoagulation and antiplatelet therapy? | Q80624555 |
| | A 2-step mechanism of arterial thrombus formation induced by human atherosclerotic plaques | Q83179292 |
| | Cilostazol stroke prevention study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarction | Q86648138 |
| | Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease | Q28196661 |
| | Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin | Q28200091 |
| | Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial | Q28209556 |
| | Clinical aspects of platelet inhibitors and thrombus formation | Q28210313 |
| | Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis | Q28211681 |
| | Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy | Q28213372 |
| | Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis | Q28218502 |
| | Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial | Q28222568 |
| | Protease-activated receptors in cardiovascular diseases | Q28261926 |
| | A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee | Q29620666 |
| | Asymptomatic embolisation for prediction of stroke in the Asymptomatic Carotid Emboli Study (ACES): a prospective observational study | Q30480493 |
| | Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank | Q30664833 |
| | Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases | Q33685876 |
| | Triggers, targets and treatments for thrombosis | Q33765444 |
| | The blood-brain barrier in brain homeostasis and neurological diseases | Q34015057 |
| | Cyclic nucleotide phosphodiesterase 1C promotes human arterial smooth muscle cell proliferation | Q34113265 |
| | Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack | Q34344580 |
| | Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome | Q34956075 |
| | Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies | Q35674441 |
| | Equivocal roles of tissue-type plasminogen activator in stroke-induced injury | Q35704593 |
| | Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding | Q36308327 |
| | Platelets as immune cells: bridging inflammation and cardiovascular disease | Q36699744 |
| | Pharmacology of emerging novel platelet inhibitors | Q37227747 |
| | Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble? | Q37441374 |
| | TP receptor antagonism: a new concept in atherothrombosis and stroke prevention | Q37480448 |
| | Medical prevention of stroke and stroke recurrence in patients with TIA and minor stroke | Q37532590 |
| | Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials | Q37590925 |
| | Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events | Q37695400 |
| | First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers | Q38296268 |
| | Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation | Q38375573 |
| | Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial | Q39889215 |
| | Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis | Q42974062 |
| | Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin | Q43073004 |
| | Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke. | Q43194111 |
| | Identification of the binding sites and selectivity of sarpogrelate, a novel 5-HT2 antagonist, to human 5-HT2A, 5-HT2B and 5-HT2C receptor subtypes by molecular modeling | Q44434675 |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | nervous system | Q9404 |
| | circulatory system | Q11068 |
| | stroke | Q12202 |
| | blood–brain barrier | Q221694 |
| | platelet aggregation inhibitors | Q721432 |
| | secondary prevention | Q2839152 |
| | cerebrovascular disease | Q3010352 |
| | preventive health services | Q65732032 |
| P304 | page(s) | 2371-2380 | |
| P577 | publication date | 2010-10-01 | |
| P1433 | published in | Journal of Cellular and Molecular Medicine | Q1524063 |
| P1476 | title | Controversies and future perspectives of antiplatelet therapy in secondary stroke prevention | |
| P478 | volume | 14 | |